Related by context. All words. (Click for frequent words.) 71 preclinical 65 preclinical studies 62 Preclinical studies 61 preclinical efficacy 61 Kinase Inhibitor 61 Small Molecule 61 preclinical toxicology 61 Presents Preclinical Data 60 Nonclinical 60 Preclinical Data 60 Antiangiogenic 60 RNAi Therapeutic 60 Pharmacodynamic 59 Preclinical Development 59 Hsp# Inhibitor 59 Omacetaxine 59 OXi# 59 Monoclonal Antibody 59 Drug Candidate 59 Romidepsin 58 Clinical 58 Clinical Trial Results 58 JAK2 Inhibitor 58 Drug Discovery 58 Phase IIa 58 ENMD # 58 Anti Tumor Activity 58 PXD# 58 vivo 58 Anti Tumor 57 preclinical models 57 Pharmacokinetic 57 Kahalalide F 57 Phase Ib clinical 57 HDAC Inhibitor 57 targeting CD# 57 Carfilzomib 57 Novel Oral 57 Pharmacokinetics 57 Signal Transduction 57 AACR NCI EORTC 56 Therapeutic Antibody 56 Systemic Delivery 56 CA4P 56 AVN# [001] 56 Clinical Trial 56 vivo preclinical 56 Factor VIIa 56 MEK inhibitor 56 Antiviral 56 histone deacetylase inhibitor 56 Preclinical Efficacy 56 histone deacetylase HDAC inhibitor 56 Phase 2b Clinical Trial 56 Preclinical Study 56 vivo efficacy 56 pharmacodynamic 56 Drug Repositioning 56 CRLX# 56 Guanilib 56 Preclinical Studies 56 Cytochrome P# 56 orally bioavailable 56 Present Preclinical Data 56 depsipeptide 56 Valortim R 56 R#/MEM # 56 Biomarker Study 55 Tyrosine Kinase Inhibitor 55 Oligonucleotide 55 mitogen activated ERK kinase 55 Pharmacokinetic PK 55 PCK# 55 cMET 55 Novel Inhibitor 55 RGB # 55 Monoclonal Antibodies 55 fosbretabulin 55 vascular disrupting agents 55 Phase III Trial 55 pan HDAC inhibitor 55 PEG Interferon lambda 55 QLT# 55 selective kinase inhibitor 55 PSN# [002] 55 INCB# [001] 55 II Clinical Trial 55 ASONEP 55 OvaRex R 55 Symadex 55 Phase 1b 55 oral prodrug 55 Aurora Kinase 55 KRN# 55 ganetespib 55 Potent Antiviral Activity 55 Novel Therapeutic 55 Novel Therapies 55 NKTR 55 Antisense Drug 55 Immunotherapeutic 55 Cancer Therapeutics 55 CEQ# 55 Kinase Inhibitors 55 NGX# 55 Pharmacological 55 Protexia ® 55 Bortezomib 55 Biomarker 55 MGCD# [001] 55 R roscovitine 55 Safinamide 55 DXL# 55 PEG SN# 55 Bioequivalence 55 Hematologic 55 vitro studies 55 Phase Ib Clinical Trial 55 XL# XL# 55 vitro experiments 55 Cloretazine R 55 MicroRNA 55 TLR antagonists 55 Phase 2a Clinical Trial 55 midstage clinical 55 Polymerase Inhibitor 55 HGS ETR1 55 ALN TTR 55 CD# CEA 55 Antitumor Activity 55 EGS# 55 Phase IIb Clinical Trial 55 RNAi Therapeutics 55 pharmacokinetic 55 Clinical Research 55 AEZS 55 ISIS # 54 Antiviral Activity 54 Universal Flu Vaccine 54 nonclinical studies 54 xenograft models 54 Trofex TM 54 Homspera 54 BAL# [001] 54 small molecule tyrosine 54 ZFP Therapeutic 54 CUDC 54 Sapacitabine 54 Proteasome 54 MLN# 54 GGF2 54 Panzem 54 preclinical pharmacology 54 Reports Preclinical Data 54 DMPK 54 Bioanalytical 54 #ME# 54 Prolongs Survival 54 Aliskiren 54 Phase 2a Trial 54 Initiates Clinical 54 VEGF Trap 54 Anticalin R 54 histone deacetylase inhibitors 54 selective androgen receptor modulator 54 PKC# 54 seliciclib CYC# 54 Prof. Gozes 54 mGluR2 NAM 54 potently inhibit 54 RDEA# 54 antisense inhibition 54 HspE7 54 Mipomersen 54 Angiolix 54 rxRNA 54 Metabolic Disease 54 transgenic mouse models 54 HCV protease 54 Novel Mechanism 54 PI3K/mTOR 54 PD LID 54 investigational humanized monoclonal antibody 54 Daclizumab 54 molecular imaging radiopharmaceutical 54 GRNCM1 54 Onalta 54 Cethromycin 54 LymphoStat B 54 MEK inhibitors 54 INT# [002] 54 Hematological Malignancies 54 CCX# 54 kinase inhibitor 54 viral kinetics 54 Phase 2b Study 54 Aplidin 54 HDAC inhibitor 54 Pimavanserin 54 Panzem R 54 PS# [001] 54 PRT# 54 Valortim 54 REP# 54 HQK 54 HSP# inhibitor 54 Aptamer 54 PDE4 inhibitor 54 Debio 53 Phase Ib 53 INGN 53 ELND# 53 JAK inhibitor 53 Sphingomab 53 Gene Expression 53 KSP inhibitors 53 IND enabling 53 phase IIb clinical 53 potent inhibitor 53 ENMD 53 Initiate Phase 53 anti angiogenic 53 Preclinical Clinical 53 Phase Ib study 53 TMC# [002] 53 Novel Small Molecule 53 TRIOLEX 53 Tβ4 53 immune modulation 53 Anti Angiogenic 53 Demonstrates Potent 53 AZD# 53 Protexia R 53 Trofex 53 Drug Metabolism 53 Phase IIa clinical 53 Preclinical Models 53 Medicinal Chemistry 53 vitro ADME 53 APOPTONE 53 Phase Ib II 53 SABCS 53 EZN 53 Hepatitis C Virus 53 PLK1 SNALP 53 Androxal TM 53 non nucleoside inhibitor 53 epigenetic therapies 53 PEGPH# 53 Drug Formulation 53 ELND-#/AZD-# 53 PSMA ADC 53 mouse xenograft models 53 Perifosine 53 Protease Inhibitor 53 enzastaurin 53 vidofludimus 53 nicotinic alpha 7 53 potent anticancer 53 JAK1 53 Orally Active 53 Phase 2b Trial 53 Cellular Immunology 53 Cloretazine ® 53 CDK inhibitor 53 Inflammatory Arthritis 53 EVIZON TM 53 atacicept 53 Naurex 53 vascular disrupting agent 53 JAK inhibitors 53 #th Annual Interscience 53 preclinical pharmacokinetic 53 Bendavia 53 novel peptide 53 Personalized Immunotherapy 53 Phase III Clinical Trial 53 Receptor Agonist 53 volociximab 53 vivo pharmacology 53 Azedra 53 Neulasta ® 53 AQ4N 53 imetelstat 53 Investigational Drug 53 TRO# 53 favorable pharmacokinetic profile 53 Archexin 53 neuroprotective 53 solithromycin 53 Meets Primary Endpoint 53 polymerase inhibitor 53 Phase IIA 53 Solid Tumor 53 pharmacological chaperone 53 Ozarelix 53 Dalbavancin 53 CYT# potent vascular disrupting 53 Solazed TM 52 selective inhibition 52 Antisense 52 Autoimmune Disease 52 HCV polymerase inhibitor 52 Dose Response 52 Presents Positive 52 Ceflatonin R 52 cannabinor 52 Xcytrin R 52 phase IIa 52 antiangiogenic activity 52 Phase IIb Trial 52 ImmunoVEX HSV2 52 CB2 selective receptor agonist 52 Tumor Targeting 52 Valortim ® 52 phase Ib 52 MEK Inhibitor 52 Lodamin 52 Cytotoxic 52 EGEN 52 FK# 52 Protein Expression 52 Mouse Model 52 Immunogenicity 52 Neuroprotection 52 anti CD3 52 Molecular Diagnostics 52 Allosteric 52 Phase IIb 52 Hedgehog pathway 52 Phase 2a trial 52 Panzem R NCD 52 BiTE Antibody 52 KNS # 52 Neurogenesis 52 Phase 2a 52 Kevetrin 52 therapeutic monoclonal antibody 52 RNAi therapeutic targeting 52 phase IIa clinical 52 immunomodulatory 52 Anticancer Drug 52 AP# [003] 52 proteasome inhibitor 52 antitumor activity 52 Pivotal Phase III 52 Autoimmunity 52 mGluR5 NAM 52 PRTX 52 Bevasiranib 52 oral bioavailability 52 induces apoptosis 52 CYT# 52 Anticancer Activity 52 xenograft 52 HGS ETR2 52 clinical trials 52 Enzastaurin 52 CGEN # 52 Wellstat 52 RNA Interference 52 GRN# 52 uricase 52 antiviral activity 52 Clinical Trial Data 52 BAL# [002] 52 ISTODAX ® 52 immunotoxin 52 Novel Antibiotic 52 pharmacokinetics PK 52 targeted radiotherapeutic 52 Blinatumomab 52 Patients Treated With 52 pharmacodynamic PD 52 novel VDA molecule 52 humanized anti 52 Chemokine 52 Mimetics 52 ProSavin 52 FOLOTYN ® 52 novel anticancer 52 Iloperidone 52 NEUGENE 52 perifosine 52 delafloxacin 52 Immunomodulatory 52 Neurodegeneration 52 Phase 2a clinical 52 Ocrelizumab 52 Neurodegenerative Disease 52 neuroprotection 52 Collaborators Publish 52 Tezampanel 52 Dose Escalation Study 52 Myelodysplastic Syndromes 52 Pharmacology 52 potent antitumor activity 52 next generation URAT1 52 Nymox NX 52 IL# PE#QQR 52 RAV# 52 antitumor 52 Completes Patient Enrollment 52 CCR2 52 Apoptone 52 Squalamine 52 Azedra TM 52 Preclinical studies suggest 52 Vicriviroc 52 Cancer Vaccines 52 Diabetic Nephropathy 52 Metastatic Melanoma 52 Belinostat 52 Trodusquemine MSI 52 novel histone deacetylase 52 Pivotal Study 52 Rheumatoid Arthritis Drug 52 Anticalin ® 52 velafermin 52 DB# [003] 52 PNP inhibitor 52 Tolerability 52 compound AEZS 52 Molecular Diagnostic 52 Therapeutic Vaccine 52 Tesetaxel 52 TRV# [001] 52 Tissue Repair 52 Hybridon 52 voreloxin 52 PK PD 52 Dendritic Cells 52 TKM ApoB 52 Onconase 52 Presents Preclinical 52 entinostat 52 pharmacodynamic parameters 52 mGlu2 3 52 Vidofludimus 52 Targeted Therapy 52 BNC# 52 Smooth Muscle 52 TLR8 agonist 52 Therapeutic Potential 52 Nucleic Acids 52 Benign Prostatic Hyperplasia 51 clinical 51 masitinib 51 ADME 51 antisense inhibitors 51 Dose Escalation 51 targeting PCSK9 51 R#/MEM 51 S/GSK# 51 Peptide 51 BiTE ® 51 XL# [003] 51 Targeted Therapies 51 vitro 51 Phase IIa trial 51 Immunotherapy 51 ARRY # 51 ospemifene 51 IIa clinical 51 Solid Tumors 51 Phase 1a clinical 51 small molecule 51 mitotic kinesins 51 Lung Cancer Drug 51 Opexa 51 Elagolix 51 oral antiviral 51 Multimeric 51 Estrogen Receptor 51 PF # [002] 51 Pharmacogenomic 51 peptide conjugated 51 AKT inhibitor 51 Tolerx 51 Antibody Discovery 51 Phase Ib clinical trials 51 VQD 51 Aurora kinase inhibitor 51 Dasatinib 51 telomerase inhibitor drug 51 triphendiol 51 Fulvestrant 51 BioFocus 51 Aflibercept 51 dasatinib Sprycel 51 Initiates Clinical Trial 51 Phase IIb clinical trials 51 vivo validation 51 GRN#L 51 JAK Inhibitor 51 HCV Protease Inhibitor 51 small molecule agonists 51 Pathway Inhibitor 51 ASH Annual Meeting 51 MOZOBIL 51 Randomized Phase 51 neuroprotective properties 51 ADX# 51 AEGR 51 non nucleoside HCV 51 ALN PCS 51 Tß4 51 kinase inhibitors 51 Potent Anti 51 ICAAC 51 antisense inhibitor 51 Pertuzumab 51 nucleoside tide 51 preclinically 51 Inhalation Solution 51 Inosine 51 mGluR5 negative 51 Genotyping 51 cathepsin K inhibitor 51 Phase IIa Clinical Trial 51 Sangamo BioSciences Announces 51 eniluracil 51 Investigational Treatment 51 laquinimod 51 Well Tolerated 51 Gleevec resistant 51 Interferon Gamma 51 ALN TTR# 51 TLR7 51 isoform selective 51 novel peptides 51 bexarotene 51 pharmacodynamic properties 51 IAP inhibitors 51 anticancer agent 51 Aurora kinase 51 Oncogene 51 Antiviral Therapy 51 HCV protease inhibitor 51 HGS# 51 HCV polymerase 51 mertansine 51 antifibrotic 51 Eg5 51 Neural Stem Cell 51 IL #E 51 Taligen Therapeutics 51 Interferon Beta 51 ADVANCE PD 51 Curaxin 51 Tumor Biology 51 Clinical Trials 51 Nasdaq IDRA today 51 Therapeutic Efficacy 51 Signaling Pathway 51 Anthracycline 51 Amrubicin 51 GLP toxicology studies 51 iroxanadine 51 tubulin inhibitor 51 telomerase therapeutic 51 Protein Kinase 51 Tyrima 51 HIV integrase inhibitor 51 MORAb 51 Elusys 51 HDAC inhibitors 51 multicenter Phase II 51 Pharmacologic 51 Phase III Trials 51 PEGylated interferon beta 1a 51 Serdaxin 51 Cytotoxicity 51 small molecule inhibitors 51 IAP inhibitor 51 Successfully Completes Phase 51 PDX pralatrexate 51 ON #.Na 51 Thiovir 51 retapamulin 51 tasimelteon 51 Translational Biology 51 Recombinant Human 51 Annamycin 51 NABTT 51 cyclophilin inhibitors 51 Clinical Efficacy 51 JVRS 51 Presents Positive Preclinical 51 selective modulator 51 Protein Therapeutics 51 CCR9 51 Long Term Efficacy 51 bortezomib Velcade 51 huN# DM1 51 pharmacokinetic PK 51 Initiated Phase 51 Rasagiline 51 Triolex 51 milatuzumab 51 HER3 51 LY# [003] 51 SERMs 51 p# inhibitor 51 Anti Infective 51 Cancer Therapeutic 51 Maxy G# 51 Proprietary Products 51 elotuzumab 51 CG# [003] 51 Immunotherapeutics 51 Anticancer Agents 51 Posiphen 51 mTOR inhibitors 50 deCODE chemistry 50 safinamide 50 TOCOSOL Paclitaxel 50 Aplidin R 50 Liposomal 50 RhuDex 50 inhibit tumor 50 clinical trial 50 BZL# 50 Charlesson 50 Cannabinoid 50 Amira Pharmaceuticals 50 ORENCIA R 50 orally dosed 50 Oncolytic Reovirus 50 Neurodegenerative Diseases 50 Pivotal Phase 50 pomalidomide 50 antiproliferative activity 50 MT# MEDI 50 biomarker discovery 50 Clofarabine 50 Study Evaluating 50 Combination REOLYSIN R 50 Autoimmune Diseases 50 Myocet 50 highly selective inhibitor 50 Cetrorelix 50 pralatrexate injection folate analogue 50 ibudilast 50 EndoTAG TM -1 50 Extracellular Matrix 50 PORxin TM 50 Patient Enrollment 50 PDE# inhibitors 50 TLR8 50 Denufosol 50 Synta Announces 50 See CLINICAL PHARMACOLOGY 50 Randomized Double blind 50 mouse xenograft 50 orally administered inhibitor 50 OHR/AVR# 50 small molecule defensin 50 GAP #B# 50 Receives Orphan Drug Designation 50 bendamustine 50 Announces Poster Presentations 50 SNALP technology 50 JAK2 inhibitors 50 PF # [001] 50 HuLuc# 50 trodusquemine 50 NEUGENE antisense 50 Phase 1b trial 50 DAVANAT 50 Investigational Compound 50 Oral Fingolimod 50 Pharmacokinetic studies 50 flavopiridol 50 Initiates Enrollment 50 Radezolid 50 Toxicogenomics 50 Autologous Stem Cell Transplantation 50 poly ADP ribose polymerase 50 Anti Infectives 50 syngeneic 50 Immutep 50 Lung Cancer Trial 50 Begins Dosing 50 ALTU 50 MGCD# [002] 50 Translational Medicine 50 Traficet EN 50 Nitazoxanide 50 evaluating tivozanib 50 Hematologic Malignancies 50 antitumoral 50 Talabostat 50 HCV SPRINT 50 Cloretazine 50 Hypercholesterolemia 50 SparVax TM 50 ATL# [001] 50 Cannabinor 50 Virologic 50 Clinical Outcome 50 AAG geldanamycin analog 50 nucleotide analog 50 antitumor effects 50 CD# monoclonal antibody 50 Oncology Drug 50 HDL Mimetic Peptide 50 Vaccine Adjuvants 50 Protease Inhibitors 50 biomarker 50 Cancer Immunotherapy 50 Psoriasis Drug 50 Preclinical Testing 50 OncoVex 50 ZFP Therapeutic TM 50 BCX# 50 OncoVEX GM CSF 50 Hematological 50 Inflammatory Disease 50 Phase Ia 50 siRNAs targeting 50 Tarvacin TM 50 Cleviprex TM clevidipine 50 Tarvacin 50 oral proteasome inhibitor 50 disease modifying 50 tezampanel 50 ATL/TV# 50 anti fibrotic 50 epothilones 50 Cloretazine R VNP#M 50 Cell Transplant 50 ZFN modified 50 Functional Genomics 50 OMP #M# 50 #th Interscience Conference 50 Molecular Therapy 50 Vaccine Adjuvant 50 Phase 2b study 50 MCSP respectively 50 Files IND 50 davunetide intranasal AL 50 Intervention Effectiveness 50 potent inhibition 50 AMPK activators 50 Anti CD# Antibody 50 KuDOS 50 Low Dose 50 Idera Pharmaceuticals 50 investigational monoclonal antibody 50 elesclomol 50 Fabry Disease 50 BioVant 50 Menerba 50 Xanafide 50 Pulmonary Arterial Hypertension 50 Phase III psoriasis 50 multitargeted 50 Molecular Virology 50 PI3K inhibitor 50 Bezielle 50 ANAVEX #-# [003] 50 rBChE 50 Phase 2b 50 Interferon alpha 50 Therapeutic Antibodies 50 Onyx Pharmaceuticals Announces 50 Immune Therapy 50 Humanized Anti 50 Vitaxin 50 GSK # 50 huC# DM4 50 EORTC NCI AACR 50 Targretin 50 generation URAT1 inhibitor 50 PHX# 50 Diabetic Macular Edema 50 Randomized Double Blind Placebo 50 mapatumumab 50 Gene Silencing 50 ongoing Phase 1b 50 Novel Compound 50 tafamidis 50 SCH # 50 Vilazodone 50 MAXY G# 50 Abstract # 50 EORTC NCI AACR Symposium 50 AACR Meeting 50 Apoptosis 50 farletuzumab 50 Vascular Disrupting Agent 50 PEG PAL 50 AeroLEF TM 50 Phase #b/#a clinical 50 Pathogenesis 50 alvespimycin 50 Phase IIb trial 50 G Protein Coupled 50 Mutagenesis 50 gastrin 50 Anti Inflammatory 50 YONDELIS R 50 Zybrestat 50 Alzhemed TM 50 ASCO GI 50 Cancer Therapies 50 anti leukemic 50 vivo toxicology 50 LB# [003] 50 Investigational Agent 49 IND submission 49 ESBA# 49 novel defensin mimetic 49 Azixa 49 Pharmacokinetics PK 49 Hedgehog pathway inhibitor 49 Clinical Study 49 Milestone Payments 49 CCR5 antagonist 49 Enzyme Replacement Therapy 49 ALB # 49 anti amnesic 49 PTH analogue 49 tosedostat 49 Spiegelmer ® 49 GeneICE 49 lenalidomide Revlimid R 49 DAVANAT ® 49 RhuDex ® 49 Phase 1b Clinical Trial 49 antiproliferative effects 49 DermaVir Patch 49 Virulizin R 49 BRIM3 49 alvimopan 49 Prodarsan ® 49 MDV# 49 Pharmacokinetic Study 49 Exherin TM 49 Upregulation 49 Renal Cell Cancer 49 Chronic Lymphocytic Leukemia 49 Golimumab 49 Cytogenetic 49 Phenoptin 49 albiglutide 49 Lisofylline LSF 49 Oral NKTR 49 ENDEAVOR IV 49 Phase 1b clinical 49 Quark Pharmaceuticals 49 Phase IIB 49 Fondaparinux 49 dacetuzumab 49 Fx #A 49 Huntexil 49 neuroprotective effects 49 Patent Covering 49 HCD# [002] 49 Refractory Angina 49 AEG# 49 Novolimus 49 dexpramipexole 49 Phase IIa trials 49 Resolvyx 49 transthyretin TTR mediated amyloidosis 49 Synthetic Chemistry 49 immunomodulatory effects 49 BRAF inhibitor 49 Resolvyx Pharmaceuticals 49 Initiate Clinical Trial 49 Neuroprotective 49 Synthetic Peptide 49 heparanase 49 Elvitegravir 49 Phase III clinical 49 oncolytic virus 49 Lupus Drug 49 HE# [002] 49 Shows Promising 49 Therapeutic Competitors Companies 49 ALN VSP 49 reversible inhibitor 49 Collaborators Present 49 Tumor Response 49 Gemin X 49 metaglidasen 49 eltrombopag 49 oral FTY# 49 Zenvia Phase III 49 Synavive 49 Inhibitory 49 REG2 49 ECTRIMS 49 Novel Antibody 49 SRT# [003] 49 Recombinant Protein 49 Valdoxan 49 NOD mouse 49 AACR symposium 49 Exelixis XL# 49 OncoVEX 49 Targeted Chemotherapy 49 HuMax EGFr 49 VEGF inhibitors 49 Mechanistic 49 Cx# [002] 49 Cara Therapeutics 49 Biotica 49 phase IIb 49 Celator 49 selective immunoproteasome inhibitor 49 Phase 1a 49 Novel Treatments 49 Regenerative Cells 49 ANAVEX #-# [001] 49 Bioprocess 49 Flow Cytometry 49 rNAPc2 49 p# inhibitors 49 radiation sensitizer 49 Curaxin CBLC# 49 Progenitor Cells 49 AVE# 49 TELINTRA 49 Vascular Targeting Agents 49 clinical pharmacology 49 ularitide 49 miR #a [001] 49 JAK2 inhibitor 49 #nd EORTC NCI 49 bicifadine 49 EnVivo Pharmaceuticals 49 First Patient Dosed 49 Actilon 49 JAK3 49 LAF# 49 SinuNase ™ 49 Capesaris 49 Bosutinib 49 calcitonin 49 potent antiproliferative 49 Bucindolol 49 pharmacokinetic studies 49 maturation inhibitor 49 CoFactor 49 Experimental Therapeutics 49 Antibody Drug Conjugate 49 cetuximab Erbitux R 49 Pharmaceuticals Initiates 49 SMT C# 49 molecular biomarkers 49 Alocrest 49 intranasal formulation 49 Hematology Annual Meeting 49 AZX# 49 Chronic Lymphocytic Leukemia CLL 49 favorable tolerability 49 pharmacodynamic effects 49 eculizumab 49 ARRY 49 apoE 49 Cardiotoxicity 49 ThermoDox ® clinical 49 antibody MT# 49 HCV protease inhibitors 49 aurora kinase 49 annexin 49 GLP toxicology 49 anti CD3 monoclonal 49 Ramoplanin 49 Lixivaptan 49 c MYC 49 CRx 49 ATL# [002] 49 P#X# 49 Intranasal 49 Zalypsis 49 riociguat 49 Trofex ™ 49 RNAi 49 NP2 Enkephalin 49 teriflunomide 49 Oncolytic 49 Atiprimod 49 Interferon Alpha 49 motexafin gadolinium Injection 49 Clinical Validation 49 Statistically Significant 49 Oligonucleotides 49 Ecallantide 49 AMD# [003] 49 Laquinimod 49 proteasome inhibitors 49 Phenserine 49 Gastric Cancer 49 immune modulatory 49 UPLYSO